Back to top

Analyst Blog

Zacks Equity Research

Positive Data on Array Oncology Candidate

JAZZ ARRY

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Array BioPharma Inc. (ARRY - Snapshot Report) recently announced positive interim results from a phase I study which is evaluating its candidate ARRY-520 combined with Onyx Pharmaceuticals, Inc.’s Kyprolis in patients suffering from relapsed or refractory multiple myeloma (MM). The results were presented at the 2013 Congress of the European Hematology Association in Sweden.

The study enrolled patients suffering from relapsed or refractory MM who were unable to tolerate Takeda Pharmaceutical Company Limited’s Velcade. Interim results from the study revealed that the combination of ARRY-520 and Kyprolis showed a disease control rate of 82% along with a clinical benefit rate of 53%. The results further revealed that the combination was well tolerated with no serious side effects.

Array also presented data on a potential patient selection marker from several studies on ARRY-520 in patients suffering from relapsed and refractory MM.

Array mentioned in its press release that data from a phase II study on ARRY-520 revealed overall survival was comparatively longer in patients with low alpha-1-acid glycoprotein (AAG) than in patients with higher AAG. This is expected to help Array to target the appropriate patient population who stand to benefit from ARRY-520 treatment.

We note that Kyprolis is indicated for the treatment of MM patients who have received at least two prior therapies including Velcade and an immunomodulatory agent. The disease had progressed in these patients on or within 60 days of completion of the last therapy.

Currently, Array BioPharma carries a Zacks Rank #3 (Hold). However, biopharma stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) presently look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%